Patent Commercialization

Patent portfolios can generate value through several distinct paths: PRODUCT COMMERCIALIZATION: the most common path — using patents defensively to protect a product business; patents deter competitors from copying; the direct commercial value comes from the product, not the patent itself; but patents block competitors from copying key features, which has indirect commercial value; LICENSING (VOLUNTARY): patents are licensed to third parties who pay royalties to practice the invention; the patent owner retains ownership; licensee pays for the right to make/use/sell products covered by the patent; licensing can be exclusive (one licensee) or non-exclusive (multiple licensees); PATENT ASSERTION/ENFORCEMENT: identifying companies that infringe the patent (without a license) and demanding payment; enforcement can be through: cease-and-desist letters; negotiated settlements; district court litigation; ITC Section 337 proceedings; PORTFOLIO SALE: selling the patent portfolio outright to another company; common when: the company changes strategic direction; the portfolio is not core to the business; the company needs capital; the buyer is typically: a competitor; a patent assertion entity (PAE); a portfolio aggregator (IV, Acacia, etc.); CROSS-LICENSING: exchanging licenses with another company; no cash changes hands; each party licenses the other's portfolio; common between: large technology companies (smartphones, semiconductors); companies with blocking patents against each other; STANDARDS ESSENTIAL PATENTS (SEP) LICENSING: patents declared essential to a technical standard (Wi-Fi, 4G/5G, HEVC) must be licensed on FRAND (fair, reasonable, and non-discriminatory) terms; SEP owners collect royalties from all implementers of the standard; highly valuable but subject to regulatory and legal scrutiny (Qualcomm, InterDigital, etc.); DONATION/DEDICATION: donating patents to a patent pool (e.g., LOT Network, Open Invention Network); provides defensive value without licensing revenue; can be used for tax deductions if donated to a nonprofit.

Building a licensing program requires a systematic approach: STEP 1 — PORTFOLIO ASSESSMENT: not all patents are worth licensing; assess each patent for: claim scope (broader → more licensing leverage); strength (prior art risk; prosecution history problems); coverage of commercial products/processes in the market; expiration date (patents expiring soon have less value); STEP 2 — IDENTIFY POTENTIAL LICENSEES: INFRINGEMENT ANALYSIS: who is practicing the invention (without a license)?; compare claim charts to public information about competitor products; reverse engineering reports; technical publications; MARKET SCAN: identify all companies in the relevant market; assess which companies are making, using, selling, or importing products that practice the claims; PRIORITIZATION: large companies first (larger royalty base); companies with clear infringement (strongest claims); companies in growing markets (longer royalty stream); STEP 3 — VALUATION AND RATE SETTING: COMPARABLE ROYALTY RATES: what do licenses in this technology area typically charge?; Georgia-Pacific factors (15-factor test for reasonable royalty from patent infringement damages); LUMP SUM vs. RUNNING ROYALTY: lump sum = one-time payment; clean; preferred by some licensees; running royalty = percentage of revenue on covered products; preferred by patent owners for growing products; TYPICAL RATES: software patents: 0.5-3% of product revenue; pharmaceutical: 2-10% of net sales; hardware: 0.25-2%; SEP/FRAND: $0.10-$1 per handset for mobile patents; STEP 4 — LICENSING OUTREACH: initial outreach: often a letter identifying the patent and suggesting a meeting; NOT a C&D letter initially (starts negotiation); NEGOTIATIONS: claim charts showing specific product coverage; royalty proposal; FRAND offer if relevant; STEP 5 — LICENSING AGREEMENT: exclusivity (exclusive → higher rate; more restrictions; non-exclusive → lower rate; multiple licensees); field of use restrictions; geographic scope; term; sublicensing rights; audit rights; most favored nation (MFN) clause.

Patent enforcement is the process of requiring unlicensed infringers to take a license or face litigation: STEP 1 — IDENTIFY INFRINGEMENT: claims analysis against the accused product/process; prepare claim charts mapping every claim element to specific features of the accused product; typically requires both legal and technical analysis; STEP 2 — PRE-SUIT INVESTIGATION: Seagate/Halo considerations: does the defendant know about the patent?; marking requirements (35 U.S.C. § 287): if products covered by the patent have not been properly marked (patent number on product or patent.com website virtual marking), damages may be limited to period after actual notice; STEP 3 — NOTICE AND NEGOTIATION: CEASE-AND-DESIST LETTER: identifies the patent; identifies the accused products; demands that infringement cease and/or the defendant take a license; this provides 'actual notice' for damages purposes; triggers Halo willfulness consideration (defendant now knows about the patent); 21-day 'safe harbor' under Rule 11 starts running; SETTLEMENT DISCUSSION: many infringement disputes are resolved by license without litigation; typically 60-80% of patent assertions settle before trial; STEP 4 — FORUM SELECTION (IF LITIGATION NEEDED): US DISTRICT COURT: must be filed in a proper venue (28 U.S.C. § 1400(b)); after TC Heartland (S.Ct. 2017): venue limited to defendant's state of incorporation OR where defendant has regular/established place of business and has infringed; Western District of Texas (Waco); District of Delaware; Northern District of California are popular venues; ITC (INTERNATIONAL TRADE COMMISSION): Section 337 investigation for imported products; very fast (12-18 months to a final determination); remedy = exclusion order (blocks importation); useful for products manufactured abroad; STEP 5 — LITIGATION: claim construction; fact discovery; expert reports; summary judgment; trial; STEP 6 — REMEDIES: INJUNCTION: enjoin continued infringement; eBay Inc. v. MercExchange (S.Ct. 2006): four-factor test; practicing patent owners more likely to get injunctions than NPEs; DAMAGES: at least a reasonable royalty; can include lost profits; willful infringement → enhanced damages up to 3×.

University technology transfer (TT) is the primary commercialization model for academic institutions: BAYH-DOLE ACT (1980): allows universities and small businesses that receive federal research funding to own and commercialize patents resulting from that research; prior to Bayh-Dole, the government owned patents resulting from federally-funded research; Bayh-Dole transformed academic IP; created the modern university tech transfer office (TTO) model; TECHNOLOGY TRANSFER OFFICES (TTOs): most research universities have dedicated TTOs; key TTO functions: invention disclosure review (researchers disclose inventions to TTO); patent filing decisions (TTO decides whether to file patents on disclosed inventions); licensing and commercialization (TTO markets inventions to industry); startup formation support (assist faculty/staff in forming spinout companies); royalty distribution (TTO manages royalties and distributes share to inventors); LICENSING MODELS: EXCLUSIVE LICENSING: grants an exclusive license to one company (often a startup); company agrees to milestones and minimum royalties; university retains rights for non-commercial research use; most common for early-stage technologies requiring significant development investment; NON-EXCLUSIVE LICENSING: multiple companies can license; lower royalty rates; common for more mature, broadly applicable technologies; START-UP FORMATION: many university inventions are commercialized through spinouts formed by faculty/grad students; TTO provides: exclusive license to the startup; business formation support; investor introductions; ROYALTY DISTRIBUTION: typical university royalty distribution: 35-50% to inventor(s); 20-30% to the inventor's department; 20-30% to the central university (TTO); some universities have formulas that shift more to inventors at high royalty levels; SUCCESSFUL EXAMPLES: Lyrica (Northwestern): $750M+ royalties; CRISPR-Cas9 (UC Berkeley/Broad Institute): billions in licensing; Gatorade (University of Florida): ~$150M+; Google PageRank (Stanford): ~$336M licensing.

Patent assertion entities (PAEs) are companies that generate revenue primarily by acquiring and licensing patents: DEFINITION: a PAE (also called a 'non-practicing entity' or 'NPE', and colloquially a 'patent troll' when used pejoratively) acquires patents and generates revenue through licensing or litigation; key distinction: the PAE does not manufacture products that practice the patents; BUSINESS MODELS: ACQUISITION-BASED PAE: buys patents from operating companies, universities, or inventors; asserts the acquired patents against manufacturers/service providers in the relevant industry; typical PAE acquisition terms: upfront payment + share of licensing revenues; operating companies often sell to PAEs when the patents no longer align with their core business; AGGREGATION-BASED PAE: IV (Intellectual Ventures): largest patent aggregator; holds 70,000+ patents; generates licensing revenue from the portfolio; ASSERTION-FOCUSED PAE: Acacia Research, WSOU Investments: specialize in aggressive patent assertion; large litigation dockets; TARGET SELECTION: PAEs typically target: large revenue companies (larger royalty base); companies that cannot afford prolonged litigation; companies that would rather settle than disclose product internals; SMALL COMPANY TARGETS: 'shakedown' letters to small companies; settlement amounts ($5,000-$50,000) often less than cost of defending; LEGAL FRAMEWORK: PAEs have all the same legal rights as operating company patent owners; eBay v. MercExchange (S.Ct. 2006): NPEs generally cannot get injunctions (they can only get monetary damages); this limits PAE leverage compared to operating companies; TC Heartland (2017): limited venue shopping — reduced ability to file in plaintiff-friendly venues; IPR/PGR: highly effective against PAE patents — PAE patents often have weaker prosecution histories; DEFENSIVE STRATEGIES: against PAE assertion: challenge patent validity via IPR; find prior art through crowd-sourcing (Ask Patents, Article One Partners); join LOT Network (licenses flow to members when PAEs acquire the patents); FRAND challenge if standards-essential claims.